SeaCrest Wealth Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

SeaCrest Wealth Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,350	Closed	-$99K	–	1955
2019 Q1	$99K	Sell	1,350 -50	-4%	-$3.4K	0.02%	694
2018 Q4	$59K	Hold	1,400	–	–	0.01%	842
2018 Q3	$66K	Hold	1,400	–	–	0.01%	902
2018 Q2	$69K	Hold	1,400	–	–	0.01%	854
2018 Q1	$43K	Buy	1,400 +600	+75%	+$16.7K	0.01%	1022
2017 Q4	$15K	Buy	+800	New	+$12.4K	﹤0.01%	1456

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SeaCrest Wealth Management's MRTX Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 1,350 shares — an estimated $99K sold.

SeaCrest Wealth Management first reported a position in MRTX in Q4 2017 and held it in 6 quarters. The position peaked at $99K in Q1 2019. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

SeaCrest Wealth Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 1,350 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $99K.
SeaCrest Wealth Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Mirati Therapeutics, Inc. Common Stock position peaked at $99K in Q1 2019.
172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.